| __timestamp | Ionis Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 9335772 |
| Thursday, January 1, 2015 | 37173000 | 12390000 |
| Friday, January 1, 2016 | 48616000 | 25602000 |
| Sunday, January 1, 2017 | 108488000 | 21262000 |
| Monday, January 1, 2018 | 244622000 | 28430000 |
| Tuesday, January 1, 2019 | 287000000 | 40849000 |
| Wednesday, January 1, 2020 | 354000000 | 60210000 |
| Friday, January 1, 2021 | 186000000 | 83664000 |
| Saturday, January 1, 2022 | 151000000 | 104097000 |
| Sunday, January 1, 2023 | 232600000 | 106916000 |
| Monday, January 1, 2024 | 267474000 |
Igniting the spark of knowledge
In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Ionis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics, saw its SG&A costs skyrocket by over 1,000% from 2014 to 2023, peaking in 2020. This surge reflects their aggressive expansion and strategic investments. Meanwhile, Iovance Biotherapeutics, known for pioneering cancer immunotherapies, experienced a more modest increase of approximately 1,050% in the same period, with a steady rise in expenses, particularly from 2019 onwards. This growth aligns with their clinical advancements and market penetration efforts. These financial insights not only highlight the companies' operational strategies but also provide a window into the broader biotech industry's economic dynamics.
AbbVie Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Insmed Incorporated or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Who Optimizes SG&A Costs Better? Ionis Pharmaceuticals, Inc. or Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited
Veracyte, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends